Bold Therapeutics, Inc.
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Phase 1
Recruiting
- Conditions
- Colorectal CancerPancreatic CancerCholangiocarcinomaGastric Cancers
- Interventions
- Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Bold Therapeutics, Inc.
- Target Recruit Count
- 220
- Registration Number
- NCT04421820
- Locations
- 🇺🇸
University of California, Los Angeles, Santa Monica, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇨🇦Cross Cancer Institue, Edmonton, Alberta, Canada
News
No news found